Missouri
Provider Communications
Update on requirement to obtain certain specialty drugs from CVS Specialty Pharmacy
As we previously communicated, Anthem Blue Cross and Blue Shield (Anthem) developed a policy requiring facilities to acquire certain select specialty pharmacy medications administered in the hospital outpatient setting through CVS Specialty Pharmacy.
This update is to advise of the following changes:
Effective for dates of service on and after June 30, 2021, the following specialty pharmacy medication will be added to the Designated Medical Specialty Pharmacy drug list and must be procured from CVS Specialty Pharmacy.
HCPCS |
Description |
Brand Name |
Q5121 |
INJECTION, INFLIXIMAB-AXXQ, BIOSIMILAR 10MG |
Avsola |
Effective immediately, the following specialty pharmacy medications have been removed from the Designated Medical Specialty Pharmacy drug list.
HCPCS |
Description |
Brand Name |
J0178 |
EYLEA |
Eylea |
J0588 |
INJECTION INCOBOTULINUMTOXIN |
Xeomin |
J2353 |
INJ OCTREOTIDE DEPOT FORM IM 1MG |
Sandostatin LAR Depot |
J1930 |
SOMATULINE DEPOT |
Somatuline Depot |
To access the current Designated Medical Specialty Pharmacy drug list, please visit anthem.com, select Providers, select Missouri, under the Provider Resources column select Forms and Guides, scroll down and select Pharmacy in the Category drop down.
Note that the Designated Medical Specialty Pharmacy drug list may be updated periodically by Anthem.
If you have questions or would like to discuss the terms and conditions for providing certain specialty medications, please contact your Anthem Contract Manager.
Thank you for your continued participation in the Anthem networks and the services you provide to our members.
Featured In:
June 2021 Anthem Provider News - Missouri